As a strategy to overcome the low response to ICBT by inhibiting sEV PD-L1 secretion in patients with cancer, the following steps were considered: (1) suppression of sEV secretion, and/or (2) suppressing cellular PD-L1 levels. Here, CD274 is linked to cancer.